Geybels et al. observed that the CAT rs1001179 polymorphism was associated with the risk of stage III/IV prostate cancer, which might be explained by the effect of CAT expression on oxidative stress and the link between increased oxidative stress and prostate cancer. The gene discussed is CAT; the disease is prostate cancer.